Antegren (Natalizumab): A new therapeutic approach for the treatment of multiple sclerosis [Antegren (Natalizumab): Ein viel versprechender neuer ansatz für die therapie der multiplen sklerose]

被引：0
|
作者：
Kümpfel T. [1 ]
Heydari N. [1 ]
Hohlfeld R. [1 ]
机构：
[1] Neurologische Klinik, Institut für Klinische Neuroimmunologie, Klinikum der Universität München-Großhadern
来源：
Der Nervenarzt | 2002年 / 73卷 / 6期
关键词：
Antegren (Natalizumab); MS therapy; Relapsing-remitting MS;
D O I：
10.1007/s00115-002-1314-3
中图分类号：
学科分类号：
摘要：
Antegren (Natalizumab) is a humanized monoclonal antibody directed against α 4-integrin. This antibody binds to the α 4 sub-unit of α 4β 1-integrin (VLA-4) and α 4β 7-integrin on leukocytes and blocks the interaction of these integrins with their ligands (VCAM and MadCAM). Disruption of these cell adhesion molecule interactions inhibits the migration of leukocytes through the blood-brain barrier and the trafficking of leukocytes through the extracellular matrix. In clinical studies, short-term treatment of patients with multiple sclerosis (MS) with antegren resulted in a clear reduction of the number of new active brain lesions on magnetic resonance imaging (MRI). Antegren was safe and well tolerated. Two large phase III studies will help to determine the longterm effect of antegren on MRI and clinical outcome in relapsing-remitting MS patients.
引用
收藏
页码：552 / 555
页数：3
相关论文
共 5 条
1